Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215178 | 0.88 | CHEK1 (0.41) | ACHECHEK1MAPTPIM1FGFR1 | |
| SCHEMBL2219568 | 0.87 | ACHE (0.43) | ACHECHEK1MAPTPIM1 | |
| SCHEMBL1561369 | 0.84 | CHEK1 (0.40) | ACHECHEK1MAPTPIM1FGFR1 | |
| SCHEMBL1560987 | 0.80 | CHEK1 (0.48) | ACHECHEK1FGFR1FGFR2FGFR4 | |
| SCHEMBL12598096 | 0.79 | NEK1 (0.39) | ACHECHEK1MAPTPIM1FGFR1 | |
| SCHEMBL1561170 | 0.79 | CHEK1 (0.38) | ACHECHEK1MAPTPIM1FGFR1 | |
| SCHEMBL473693 | 0.79 | CHEK1 (0.40) | ACHECHEK1MAPTPIM1FGFR1 | |
| SCHEMBL2216558 | 0.76 | CHEK1 (0.54) | ACHECHEK1MAPTPIM1FGFR1 | |
| SCHEMBL11907769 | 0.75 | MERTK (0.39) | ACHECHEK1PIM1FGFR2KDR | |
| SCHEMBL1980500 | 0.74 | PIM1 (0.49) | ACHECHEK1MAPTPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | claimed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | ACHE 4362/4885CHEK1 786/4885MAPT 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.